Cargando…
Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project
OBJECTIVES: Lung cancer is an important cause of mortality in the United States. Targeted mutation analysis has the potential to alter mortality in those with non-small-cell lung cancer. As such, the importance of timely tissue turnaround time (TAT) is substantial. We evaluated TAT at Mayo Clinic Ar...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Scientific Scholar
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159331/ https://www.ncbi.nlm.nih.gov/pubmed/37151481 http://dx.doi.org/10.25259/Cytojournal_47_2021 |
_version_ | 1785037118001643520 |
---|---|
author | Nokes, Brandon Baumann, Coralie Magallanez, Kim Cartin-Ceba, Rodrigo Spiczka, Amy Wendel Wendel Malhotra, Atul Chen, Longwen |
author_facet | Nokes, Brandon Baumann, Coralie Magallanez, Kim Cartin-Ceba, Rodrigo Spiczka, Amy Wendel Wendel Malhotra, Atul Chen, Longwen |
author_sort | Nokes, Brandon |
collection | PubMed |
description | OBJECTIVES: Lung cancer is an important cause of mortality in the United States. Targeted mutation analysis has the potential to alter mortality in those with non-small-cell lung cancer. As such, the importance of timely tissue turnaround time (TAT) is substantial. We evaluated TAT at Mayo Clinic Arizona and found it to be delayed relative to national standards. MATERIAL AND METHODS: We conducted a series of plan, do, study, and act (PDSA) cycles at a single institution to identify areas for improvement with our lung cancer genomic testing. We assembled a multidisciplinary team and held serial meetings to discuss data from each PDSA cycle. RESULTS: Using PDSA cycles and multidisciplinary discussions, we were able to identify a number of process limitations slowing TAT. We were then able to generate enhanced and timely communication between providers and pathology, educate and enforce the order/requisition workflow, and establish pathology accessioning with lung cancer specimens top priority. CONCLUSION: We were able to generate and implement a standard operating procedure for genomic testing of lung cancer specimens at our institution, thereby reducing tissue TAT. |
format | Online Article Text |
id | pubmed-10159331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Scientific Scholar |
record_format | MEDLINE/PubMed |
spelling | pubmed-101593312023-05-05 Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project Nokes, Brandon Baumann, Coralie Magallanez, Kim Cartin-Ceba, Rodrigo Spiczka, Amy Wendel Wendel Malhotra, Atul Chen, Longwen Cytojournal Research Article OBJECTIVES: Lung cancer is an important cause of mortality in the United States. Targeted mutation analysis has the potential to alter mortality in those with non-small-cell lung cancer. As such, the importance of timely tissue turnaround time (TAT) is substantial. We evaluated TAT at Mayo Clinic Arizona and found it to be delayed relative to national standards. MATERIAL AND METHODS: We conducted a series of plan, do, study, and act (PDSA) cycles at a single institution to identify areas for improvement with our lung cancer genomic testing. We assembled a multidisciplinary team and held serial meetings to discuss data from each PDSA cycle. RESULTS: Using PDSA cycles and multidisciplinary discussions, we were able to identify a number of process limitations slowing TAT. We were then able to generate enhanced and timely communication between providers and pathology, educate and enforce the order/requisition workflow, and establish pathology accessioning with lung cancer specimens top priority. CONCLUSION: We were able to generate and implement a standard operating procedure for genomic testing of lung cancer specimens at our institution, thereby reducing tissue TAT. Scientific Scholar 2023-04-05 /pmc/articles/PMC10159331/ /pubmed/37151481 http://dx.doi.org/10.25259/Cytojournal_47_2021 Text en © 2023 Cytopathology Foundation Inc, Published by Scientific Scholar https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Research Article Nokes, Brandon Baumann, Coralie Magallanez, Kim Cartin-Ceba, Rodrigo Spiczka, Amy Wendel Wendel Malhotra, Atul Chen, Longwen Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project |
title | Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project |
title_full | Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project |
title_fullStr | Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project |
title_full_unstemmed | Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project |
title_short | Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project |
title_sort | improving the process of ordering outside genomic testing for lung cancer fna and small biopsy specimens – a multidisciplinary quality improvement project |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159331/ https://www.ncbi.nlm.nih.gov/pubmed/37151481 http://dx.doi.org/10.25259/Cytojournal_47_2021 |
work_keys_str_mv | AT nokesbrandon improvingtheprocessoforderingoutsidegenomictestingforlungcancerfnaandsmallbiopsyspecimensamultidisciplinaryqualityimprovementproject AT baumanncoralie improvingtheprocessoforderingoutsidegenomictestingforlungcancerfnaandsmallbiopsyspecimensamultidisciplinaryqualityimprovementproject AT magallanezkim improvingtheprocessoforderingoutsidegenomictestingforlungcancerfnaandsmallbiopsyspecimensamultidisciplinaryqualityimprovementproject AT cartincebarodrigo improvingtheprocessoforderingoutsidegenomictestingforlungcancerfnaandsmallbiopsyspecimensamultidisciplinaryqualityimprovementproject AT spiczkaamywendelwendel improvingtheprocessoforderingoutsidegenomictestingforlungcancerfnaandsmallbiopsyspecimensamultidisciplinaryqualityimprovementproject AT malhotraatul improvingtheprocessoforderingoutsidegenomictestingforlungcancerfnaandsmallbiopsyspecimensamultidisciplinaryqualityimprovementproject AT chenlongwen improvingtheprocessoforderingoutsidegenomictestingforlungcancerfnaandsmallbiopsyspecimensamultidisciplinaryqualityimprovementproject |